Article
NeurologyLive Friday 5 — January 24, 2020
Author(s):
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 24, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Podcast: Why EMS Transport Protocols Matter in Stroke
Episode 6, "Time Is Brain: Why EMS Transport Protocols Matter" features an interview with Donald Frei, MD, a neurointerventional surgeon at Swedish Medical Center and Radiology Imaging Associates in Denver, Colorado, and past president of the Society for Neurointerventional Surgery.
2: Humble Pie: The Art of Eating Your Words in Medicine
Danielle B. Cross, MD, MS, a neurology resident in training, shares her thoughts on the importance of humility in medicine—an "acquired taste as mandatory a part of the diet of any well-meaning clinician as vegetables."
3: Risdiplam Meets Primary End Point in SMA Type 1
Part 2 of the pivotal FIREFISH clinical trial met its primary end point in infants aged 1 to 7 months with Type 1 spinal muscular atrophy, with statistically significant and medically meaningful motor milestone improvements.
4: Suvorexant Increases Sleep Time in Patients With Alzheimer Dementia, Insomnia
The drug proved effective in extending total sleep time over a 4-week study period, with minimal adverse events observed.
5: FDA Gives Green Light to Healey ALS Platform Trial
The first trial of its kind in amyotrophic lateral sclerosis will first examine 3 drugs and add additional treatments as more become available.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
